Apr. 25 at 6:47 PM
$SLS Even the most doltish among us can tell, the SLS009 57% ORR Rate in End Stage Relapsed Refractory AML-MR patients, who've Failed All Treatments, will be Better in a much Healthier, less compromised Front Line AML-MR Patient Setting.
- Then add in the Increased Potency and Efficacy of the Enhanced Dosing ...
- There are NO Effective Treatments for AML-MR / Tp53 Asxl1+ UNTIL NOW.
SLS009 is worth at Least the
$4.9B
$GILD Paid for
$FTSV after its P1B AML-MR Data ... Just SLS009 is worth
$27 Per Share RIGHT NOW to big Pharma.
CDKinase INHIBITORS are Extremely Valuable ....
$LLY $PFE
